Artrya (ASX:AYA): Disappointing 4Q26 cash flow

248 Views29 Jul 2026 22:00

Issuer-paid

SUMMARY

Artrya released its 4Q26 cash flow report today.
Overall, it was a disappointing read (shares closed down -6.3%), with cash receipts below expectations, a slower-than-expected rollout of Salix to the foundation partners and no real news regarding the submission of Salix Coronary Flow for FDA clearance.
Conference call: 30th July, 10:00 am AEST/8:00 am AWST Pre-register: https://artrya.zoom.us/webinar/register/WN_f2Lc_hvER3uq6UFuGVaGYw The following is a summary of the key points from Artrya’s 4Q26 cash flow announcement.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream